Article

Blood line = life line?

Will findings by Worcester, MA-based Advanced Cell Technologies (ACT) on large-scale blood production from stem cells help the company pull in some much-needed capital? By now you've likely seen reports on a linkurl:paper;http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2008-05-157198v1 appearing today in Blood in which researchers differentiated human embryonic stem cells into oxygen-carrying blood cells, in large quantity. The results suggest it may be possible to create

Written byAndrea Gawrylewski
| 1 min read
Save for Later
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Will findings by Worcester, MA-based Advanced Cell Technologies (ACT) on large-scale blood production from stem cells help the company pull in some much-needed capital? By now you've likely seen reports on a linkurl:paper;http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2008-05-157198v1 appearing today in Blood in which researchers differentiated human embryonic stem cells into oxygen-carrying blood cells, in large quantity. The results suggest it may be possible to create mass quantities of blood for transfusions and blood banks. It's a promising advance in applying embryonic stem cell technology, but what's also interesting about this study is its timing. Just linkurl:last month;http://www.the-scientist.com/blog/display/54884/ ACT stated in a Security and Exchange Commission filing that the biotech did not have funds to stay open through the end of the month. All the press "might help a little" in attracting some new investment to the company, Robert Lanza, chief scientific officer at ACT and senior author on the recent paper, told The Scientist in an Email. "But most potential investors already know what we're doing." Lanza added that the company has several papers in the pipeline. Last week, the Worcester Business Journal linkurl:reported;http://www.wbjournal.com/news41387.html that ACT had licensed some of its embryonic stem cell technology and 140 stem cell lines to Embryome, a subsidiary of BioTime Inc. The upfront payment was $250,000, with the paper reporting that ACT could stand to make $1.25 million from the deal. But Lanza told the linkurl:Boston Globe;http://www.boston.com/business/healthcare/articles/2008/08/20/stem_cells_may_bring_bottomless_blood_bank/ today that the company is still scrambling for funds, "raising small amounts of money and working on larger deals."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Join for free today
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Share

Related Research Resources

A menstrual cup and storage bag on a blue background

Collecting Insights into the Vaginal Microbiome and Menstrual Health

Article

DNA Genotek logo
An illustration of PFAS in the bloodstream.

Uncovering the Harmful Effects of PFAS Exposure on the Human Body

Infographic

An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

Infographic

sartorius logo
Abstract paint splashes resembling viral particles on a colorful background.

Accelerating Pathogen Detection with Nanopore Sequencing

Whitepaper

Oxford Nanopore Technologies Logo
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Product News

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo